These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33860199)

  • 21. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.
    Jourdan T; Djaouti L; Demizieux L; Gresti J; Vergès B; Degrace P
    Diabetes; 2010 Apr; 59(4):926-34. PubMed ID: 20110567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.
    Knani I; Earley BJ; Udi S; Nemirovski A; Hadar R; Gammal A; Cinar R; Hirsch HJ; Pollak Y; Gross I; Eldar-Geva T; Reyes-Capo DP; Han JC; Haqq AM; Gross-Tsur V; Wevrick R; Tam J
    Mol Metab; 2016 Dec; 5(12):1187-1199. PubMed ID: 27900261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
    Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
    J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists.
    Sharma MK; Murumkar PR; Kanhed AM; Giridhar R; Yadav MR
    Eur J Med Chem; 2014 May; 79():298-339. PubMed ID: 24747288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.
    Jourdan T; Demizieux L; Gresti J; Djaouti L; Gaba L; Vergès B; Degrace P
    Hepatology; 2012 Mar; 55(3):790-9. PubMed ID: 21987372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
    Cota D; Sandoval DA; Olivieri M; Prodi E; D'Alessio DA; Woods SC; Seeley RJ; Obici S
    Obesity (Silver Spring); 2009 Aug; 17(8):1641-5. PubMed ID: 19325539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NESS06SM reduces body weight with an improved profile relative to SR141716A.
    Mastinu A; Pira M; Pinna GA; Pisu C; Casu MA; Reali R; Marcello S; Murineddu G; Lazzari P
    Pharmacol Res; 2013 Aug; 74():94-108. PubMed ID: 23756200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats.
    Lazzari P; Serra V; Marcello S; Pira M; Mastinu A
    Eur Neuropsychopharmacol; 2017 Jul; 27(7):667-678. PubMed ID: 28377074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.
    Nogueiras R; Veyrat-Durebex C; Suchanek PM; Klein M; Tschöp J; Caldwell C; Woods SC; Wittmann G; Watanabe M; Liposits Z; Fekete C; Reizes O; Rohner-Jeanrenaud F; Tschöp MH
    Diabetes; 2008 Nov; 57(11):2977-91. PubMed ID: 18716045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.
    Hurst DP; Lynch DL; Barnett-Norris J; Hyatt SM; Seltzman HH; Zhong M; Song ZH; Nie J; Lewis D; Reggio PH
    Mol Pharmacol; 2002 Dec; 62(6):1274-87. PubMed ID: 12435794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyrazole antagonists of the CB1 receptor with reduced brain penetration.
    Fulp A; Zhang Y; Bortoff K; Seltzman H; Snyder R; Wiethe R; Amato G; Maitra R
    Bioorg Med Chem; 2016 Mar; 24(5):1063-70. PubMed ID: 26827137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
    Meschler JP; Kraichely DM; Wilken GH; Howlett AC
    Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
    Chen W; Chen Z; Xue N; Zheng Z; Li S; Wang L
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug; 386(8):721-32. PubMed ID: 23620336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice.
    Jin K; Xie L; Kim SH; Parmentier-Batteur S; Sun Y; Mao XO; Childs J; Greenberg DA
    Mol Pharmacol; 2004 Aug; 66(2):204-8. PubMed ID: 15266010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent.
    Azar S; Udi S; Drori A; Hadar R; Nemirovski A; Vemuri KV; Miller M; Sherill-Rofe D; Arad Y; Gur-Wahnon D; Li X; Makriyannis A; Ben-Zvi D; Tabach Y; Ben-Dov IZ; Tam J
    Mol Metab; 2020 Dec; 42():101087. PubMed ID: 32987186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy in diet-induced obese mice of the hepatotropic, peripheral cannabinoid 1 receptor inverse agonist TM38837.
    Cooper ME; Nørregaard PK; Högberg T; Andersson G; Receveur JM; Linget JM; Elling CE
    Br J Pharmacol; 2024 Jun; ():. PubMed ID: 38886096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabinoid CB
    Chen W; Liu H; Guan H; Xue N; Wang L
    Eur J Pharmacol; 2017 Nov; 814():232-239. PubMed ID: 28844874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
    Silvestri C; Di Marzo V
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice.
    Chen B; Hu N
    Braz J Med Biol Res; 2017 May; 50(6):e6141. PubMed ID: 28492810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.